About Ovensa

Ovensa Inc. is a Canadian, preclinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform, with mucosal and brain-barrier crossing properties, to generate advanced, multi-combination nanotherapeutics, that enhance the bioavailability and the targeted intracellular uptake of small molecules and biologics through oral and other routes of administration. Ovensa focuses in oncology and neurodegenerative diseases where its platform can significantly improve therapeutic outcomes.


Ovensa is seeking for strategic partnerships with pharmaceutical and biotech companies interested in developing targeted biologic and small molecule candidates with improved bioavailability as well as exploring non-parenteral routes of administration.